secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cadrenal Therapeutics, Inc. (CVKD)
CIK:        0001937993
Form:       8-K
Filed at:   2026-04-01T23:59:59+00:00
Accession:  0001213900-26-038014
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 1.01, 3.02, 3.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cadrenal Therapeutics receives $2.5M gross proceeds from warrant exercise, issues new warrants
--------------------------------------------------------------------------------

- Existing warrant holder exercises 571,430 shares at reduced price of $4.50 per share, yielding $2.5M gross proceeds.
- Company issues new Series B-1 (5-year term) and Series B-2 (18-month term) warrants to purchase 571,430 shares each at $4.50.
- Placement agent H.C. Wainwright receives 7% cash fee ($175k) and warrants for 37,143 shares at $5.625.
- Expected closing on April 1, 2026; net proceeds used for working capital.
- Company agrees to file resale registration statement for new warrant shares within 30 days.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1937993/000121390026038014/0001213900-26-038014-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1937993/000121390026038014/ea0284507-8k_cadrenal.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-038014

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer